Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 3OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Cyclophosphamide 11Doxorubicin 9Vincristine 8Methotrexate 6nelarabine 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Leucovorin 5Cytarabine 5tanespimycin 4merphos 4fludarabine phosphate 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Etoposide 4Dexamethasone 4Cyclosporine 4Calcium Dobesilate 4Bortezomib 4prednylidene 3pegaspargase 3deltacortene 3azathiopurine 3Vorinostat 3Thioguanine 3Radiotherapy 3Pharmacogenomic Testing 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × calaspargase pegol × Clear all
NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

National Cancer Institute (NCI)

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡